Key Points
- Chairman Adam Craig purchased 4,600 X4 Pharmaceuticals shares at an average price of $2.58, investing $11,868 and increasing his stake by 1.4% to 333,251 shares.
- XFOR shares opened at $2.75 and remain well below their 50-day and 200-day moving averages. The company recently beat quarterly EPS and revenue estimates, though it continues to report significant losses.
- Analyst sentiment is moderately bullish, with a consensus “Moderate Buy” rating and an average price target of $11.25, while institutional investors and hedge funds own 72.03% of the stock.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) Chairman Adam Craig purchased 4,600 shares of the company's stock in a transaction dated Friday, October 16th. The stock was acquired at an average price of $2.58 per share, with a total value of $11,868.00. Following the completion of the transaction, the chairman owned 333,251 shares of the company's stock, valued at $859,787.58. This represents a 1.40% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
X4 Pharmaceuticals Stock Up 6.2%
Shares of XFOR stock opened at $2.75 on Tuesday. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The stock has a 50 day simple moving average of $3.50 and a 200 day simple moving average of $3.87. X4 Pharmaceuticals, Inc. has a 1 year low of $2.43 and a 1 year high of $4.83.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. The business had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. Equities analysts expect that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On X4 Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the company. WINTON GROUP Ltd lifted its holdings in shares of X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company's stock worth $67,000 after acquiring an additional 3,800 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth approximately $313,000. AXQ Capital LP bought a new position in X4 Pharmaceuticals in the second quarter valued at approximately $107,000. Wellington Management Group LLP bought a new position in X4 Pharmaceuticals in the second quarter valued at approximately $242,000. Finally, Bank of New York Mellon Corp bought a new position in X4 Pharmaceuticals in the second quarter valued at approximately $917,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have recently weighed in on XFOR. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an "overweight" rating and a $11.00 target price for the company. Weiss Ratings upgraded X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 2nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.25.
Check Out Our Latest Research Report on XFOR
About X4 Pharmaceuticals
(
Get Free Report)
X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company's research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.
X4's primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
